Ann: Update on Phase I/II Clinical Trial for Burn Wound Infection, page-72

For the hundredth time,,, ignore rykster hes a disgruntled disenfranchised ex employee
no possible resistance build up by any bacteria because of its novel mechanism of action that attaches to and dissolves the outer celluar layer of the bacteria
it would be like you mutating your skin to some other chemical makeup like silica or something silly
then it probably wouldnt be a bacteria anymore anyway

end of phase 1/11 burns trials satisfactorily done and all required data accumulated and teported probably by mid next year at lAtest likely a lot earlier
phase 1 human trial likely done by end of first qtr 2022
phase 11 say year end 2022
phase 111 2-3 years
but by then this will be totally different company in valuation terms
its an open ended uncapped valuation as a replacement that for declining penicillin efficacy and growing fast world wide expansion of multi drug resistant bacteria to all known current penicillin derivatives
major major value here to the patient investors who can understand the research statements and claims
pre clinical trials have been outstanding
animal trials showed no toxicity at relevant treatment thresholds
hope that helps the newbies coming on board
but please do read all you can of the widely disseminated discussion of all aspects and applications for recce drugs
its there for the asking and some excellent video presentations by james graham and michelle deliza posted on the recce website and on u tube auzbiz etc

be patient its only early days but the rewards in the future sre just outstanding
i m biased , im heavily invested , for some time now
im a buyer on weakness when i can find funds
i am a retired professional fund manager from a 35 year career in multiple investment houses
but dont take my word for it dyor and make your own risk investment decisions